Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| 제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
|---|---|---|---|---|---|
| BTK-H55H3 | Human | Human BTK Protein, His Tag (active enzyme) |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Orelabrutinib | ICP-022; BIIB-135 | Approved | Beijing Innocare Pharma Tech Co Ltd | 宜诺凯, INNOBRUKA, YINUOKAI | Mainland China | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Beijing Innocare Pharma Tech Co Ltd | 2020-12-25 | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma; Hepatic Insufficiency; Leukemia, B-Cell; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Helicobacter pylori infection; Lymphoma, B-Cell, Marginal Zone; Purpura, Thrombocytopenic, Idiopathic; Lymphoma, B-Cell | Details |
| Ibrutinib | PCI-32765; CRA-032765; JNJ-54179060; PCI-32765-00 | Approved | Pharmacyclics Llc | Imbruvica, 亿珂 | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Pharmacyclics Inc | 2013-11-13 | Waldenstrom Macroglobulinemia; Monoclonal Gammopathy of Undetermined Significance; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Food Hypersensitivity; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Prostatic Neoplasms; Leukemia, Prolymphocytic, B-Cell; Hepatic Insufficiency; Leukemia, B-Cell; Lymphoproliferative Disorders; Leukemia, Mast-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms, Gonadal Tissue; Intraocular Lymphoma; Lung Neoplasms; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Lymphoma, T-Cell; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Leukemia, Biphenotypic, Acute; Hepatitis B, Chronic; Leukemia; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Immunoproliferative Small Intestinal Disease; Hematopoietic stem cell transplantation (HSCT); Leukemia, Myelogenous, Chronic; HIV Infections; Hematologic Neoplasms; Solid tumours; Carcinoid Tumor; Leukemia, Lymphoid; Esophageal Neoplasms; Lymphoma, B-Cell | Details |
| Acalabrutinib | ACP-196 | Approved | Astrazeneca Plc, Acerta Pharma Llc | Calquence, 康可期 | United States | Lymphoma, Mantle-Cell | Astrazeneca Plc | 2017-10-31 | Multiple Myeloma; Leukemia, Prolymphocytic; Carcinoma, Non-Small-Cell Lung; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Non-Hodgkin; Hepatic Insufficiency; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Food Hypersensitivity; Richter's Syndrome; Anemia, Hemolytic, Autoimmune; Lymphoma, Mantle-Cell; Drug-Related Side Effects and Adverse Reactions; Pancreatic Neoplasms; Hodgkin Disease; Carcinoma, Transitional Cell; Arthritis, Rheumatoid; Graft vs Host Disease; Neoplasms; Glioblastoma; Coronavirus Disease 2019 (COVID-19); Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphoid; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Hematologic Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell | Details |
| Pirtobrutinib | LY 3527727; RXC-005; LOXO-305 | Approved | Redx Pharma Ltd | Jaypirca | United States | Lymphoma, Mantle-Cell | Loxo Oncology Inc | 2023-01-27 | Purpura, Thrombocytopenic, Idiopathic; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia; Leukemia, Lymphoid; Renal Insufficiency; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Multiple Myeloma; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Hepatic Insufficiency; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Tirabrutinib hydrochloride | GS-4059; ONO-4059 | Approved | Ono Pharmaceutical Co Ltd | ベレキシブル, Velexbru | Japan | Lymphoma | Ono Pharmaceutical Co Ltd | 2020-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Sjogren's Syndrome; Chronic Urticaria; Arthritis, Rheumatoid; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
| Zanubrutinib | BGB-3111 | Approved | BeOne Medicines Ltd | Brukinsa, 百悦泽 | United States | Lymphoma, Mantle-Cell | Beigene (Usa) Inc | 2019-11-14 | Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Lymphoma, T-Cell; Lymphoma; Waldenstrom Macroglobulinemia; Hepatic Insufficiency; Leukemia, B-Cell; Anemia, Hemolytic, Autoimmune; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, B-Cell; Lung Diseases; Glomerulonephritis, Membranous; Lupus Nephritis; Neoplasms; Coronavirus Disease 2019 (COVID-19); Lymphoma, Large B-Cell, Diffuse; Immunoglobulin G4-Related Disease; Nephrosis; Leukemia; Solid tumours; Lymphoma, B-Cell, Marginal Zone | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Nemtabrutinib | ARQ-531; MK-1026 | Phase 3 Clinical | Arqule Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Richter's Syndrome; Hepatic Insufficiency; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Fenebrutinib | G-0853; RG-7845; GDC-0853; RO-7010939 | Phase 3 Clinical | Genentech Inc | Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lupus Erythematosus, Systemic; Urticaria; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Remibrutinib | LOU-064; LOU064-NXA; NVP-LOU064-NXA | Phase 3 Clinical | Novartis Pharma Ag | Multiple Sclerosis, Relapsing-Remitting; Myasthenia Gravis; Chronic Urticaria; Sjogren's Syndrome; Multiple Sclerosis; Dermatitis; Urticaria; Asthma; Hepatic Insufficiency; Sjogren-Larsson Syndrome; Peanut Hypersensitivity; Hidradenitis Suppurativa; Disease Susceptibility | Details |
| Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
| Tolebrutinib | PRN-2246; SAR-442168 | Phase 3 Clinical | Principia Biopharma Inc | Myasthenia Gravis; Renal Insufficiency; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Hepatic Insufficiency | Details |
| Abivertinib | A-610MA; AC-0010; AC-0100; AC-001; AC-0010MA; AC-0100-Maleate; EX-ACEA0010MA | Phase 3 Clinical | Zhejiang Acea Pharmaceutical Co Ltd, Hangzhou Acea Pharmaceutical Research Co Ltd | Lymphoma, B-Cell; Coronavirus Disease 2019 (COVID-19); Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Atuzabrutinib | PRN-473; SAR-444727 | Phase 2 Clinical | Principia Biopharma Inc, Sanofi | Dermatitis, Atopic | Details |
| Elsubrutinib/Upadacitinib | ABBV-599 | Phase 2 Clinical | Abbvie Inc | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic | Details |
| Poseltinib | HM-71224; LY3337641; NB-02 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Central Nervous System Lymphoma; Primary vitreoretinal lymphoma | Details |
| TAS-5315 | TAS-5315 | Phase 2 Clinical | Taiho Pharmaceutical Co Ltd | Chronic Urticaria; Arthritis, Rheumatoid | Details |
| HZ-A-018 | HZ-A-018 | Phase 2 Clinical | Hangzhou Yuzheng Pharmaceutical Technology Co Ltd, HeaZen Therapeutics Co Ltd | Lymphoma, B-Cell; Multiple Sclerosis; Neuromyelitis Optica; Thrombocytopenia; Central Nervous System Lymphoma | Details |
| Branebrutinib | BMS-986195 | Phase 2 Clinical | Bristol-Myers Squibb Company | Arthritis, Rheumatoid; Sjogren's Syndrome; Immune System Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic | Details |
| BIIB-091 | BIIB-091 | Phase 2 Clinical | Biogen Inc | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis | Details |
| WXFL10230486 | WXFL-10230486; WX-486; HWH-486 | Phase 2 Clinical | Wuxi Apptec Co Ltd, Humanwell Healthcare (Group) Co Ltd | Chronic Urticaria; Arthritis, Rheumatoid | Details |
| M-7583 | M7583; M-7583 | Phase 2 Clinical | Merck & Co Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Edralbrutinib | TG-1701; SHR-1459 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd, Jiangsu shengdi Medicine Co Ltd | Lymphoma, B-Cell; Nephrosis; Arthritis, Rheumatoid; Autoimmune Diseases; Glomerulonephritis, Membranous; Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| TL-925 | TL-925 | Phase 2 Clinical | Telios Pharmaceuticals | Dry Eye Syndromes; Conjunctivitis, Allergic | Details |
| HBW-3210 | HBW-3210; HBW3210 | Phase 2 Clinical | Chengdu Haibowei Pharmaceutical Co Ltd | Lymphoma, B-Cell | Details |
| TQB-3702 | TQB3702; TQB-3702 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Lymphoma, B-Cell; Hematologic Neoplasms; Neoplasms; Chronic Urticaria; Lupus Erythematosus, Systemic | Details |
| HBW-3220 | HBW-3220; HBW-3-10; HBW-003 | Phase 2 Clinical | Chengdu Haibowei Pharmaceutical Co Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Lymphoma, Non-Hodgkin; Glomerulonephritis | Details |
| DZD-8586 | DZD-8586 | Phase 2 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| BGB-16673 | BGB-16673; [14C]-BGB-16673 | Phase 2 Clinical | BeOne Medicines Ltd | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| HMPL-760 | HMPL-760; HMPL760 | Phase 2 Clinical | Hutchison Medipharma Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Richter's Syndrome; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Rocbrutinib | LP-168; NWP-775 | Phase 2 Clinical | Newave Pharmaceutical Inc | Lymphoma, B-Cell, Marginal Zone; Hematologic Neoplasms; Lymphoma, B-Cell; Leukemia, Hairy Cell; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Neuromyelitis Optica; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| MH-048 | MH-048; MH048 | Phase 2 Clinical | Minghui Pharmaceutical (Shanghai) Co Ltd | Lymphoma, B-Cell | Details |
| Elsubrutinib | ABBV-105 | Phase 2 Clinical | Abbvie Ltd | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic | Details |
| CX-1440 | CX1440; CX-1440 | Phase 2 Clinical | Hangzhou Sanyintai Pharmaceutical Technology Co Ltd, Hangzhou Aojin Biomedical Technology Co Ltd | Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Graft vs Host Disease; Multiple Sclerosis; Lupus Erythematosus, Systemic; Urticaria; Leukemia, B-Cell; Thrombocytopenia | Details |
| JNJ-64264681 | JNJ-4681; JNJ-64264681 | Phase 1 Clinical | Johnson & Johnson | Solid tumours; Hematologic Neoplasms; Neoplasms; Myelodysplastic Syndromes; Prostatic Neoplasms, Castration-Resistant; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| PCI-45292 | Phase 1 Clinical | Pharmacyclics Llc | Arthritis, Rheumatoid; Autoimmune Diseases | Details | |
| BMS-935177 | Phase 1 Clinical | Bristol-Myers Squibb Company | Immune System Diseases | Details | |
| BT-1053 | BT-1053 | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd, ScinnoHub Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| BTK-Max | BTK-Max | Phase 1 Clinical | Bristol-Myers Squibb Company | Arthritis, Rheumatoid; Psoriasis | Details |
| DTRMWXHS-12 | DTRMWXHS-12; DTRM-12 | Phase 1 Clinical | Zhejiang Dtrm Biopharma Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| FCN-647 | FCN-647 | Phase 1 Clinical | Fochon Pharmaceuticals Ltd | Lymphoma, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| SN-1011 | SN-1011 | Phase 1 Clinical | Sinomab Bioscience Ltd | Lupus Erythematosus, Systemic | Details |
| AC-0058TA | AC-0058; AC-0058TA | Phase 1 Clinical | Hangzhou Acea Pharmaceutical Research Co Ltd, Zhejiang Acea Pharmaceutical Co Ltd | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic | Details |
| BI-BTK-1 | BI-BTK-1 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Lupus Nephritis | Details |
| DTRM-505 | DTRM-505 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| DWP-212525 | DWP-212525 | Phase 1 Clinical | Daewoong Pharmaceutical Co Ltd | Autoimmune Diseases; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Pemphigus | Details |
| DWP-213388 | DWP-213388 | Phase 1 Clinical | Daewoong Pharmaceutical Co Ltd | Autoimmune Diseases | Details |
| NX-5948 | NX-5948 | Phase 1 Clinical | Nurix Therapeutics Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| UBX-303061 | UBX-303061 | Phase 1 Clinical | Ubix Therapeutics Inc | Lymphoma, B-Cell | Details |
| [14C]Pirtobrutinib | LOXO-305; [14C]RXC-005; RXC-005; [14C]LOXO-305 | Phase 1 Clinical | Redx Pharma Ltd | Details | |
| ANG-0623 | ANG-0623; ANG0623 | Phase 1 Clinical | Angel Pharmaceuticals Co Ltd | Multiple Sclerosis | Details |
| XS-04 | XS-04 | Phase 1 Clinical | Jiangsu Xingsheng Xinhui Pharmaceutical Co Ltd | Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse | Details |
| HZ-Q1070 | HZ-Q1070; HZ-Q-1070 | Phase 1 Clinical | HeaZen Therapeutics Co Ltd | Lymphoma, B-Cell; Neoplasms | Details |
| ABBV-101 | ABBV-101 | Phase 1 Clinical | Abbvie Inc | Hematologic Neoplasms | Details |
| IMG-004 | IMG-004 | Phase 1 Clinical | Hutchmed (China) Ltd | Chronic Urticaria | Details |
| XNW-1011 | EVER001; EVER-001; XNW1011; XNW-1011; SN-1011; SN1011 | Phase 1 Clinical | Suzhou Sinovent Pharmaceuticals Co Ltd, Sinomab Bioscience Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Glomerulonephritis, Membranous; Multiple Sclerosis; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Nephrotic Syndrome; Pemphigus | Details |
| AC-0676 | AC0676; AC-676; AC676; AC-0676 | Phase 1 Clinical | Accutar Biotechnology Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Autoimmune Diseases | Details |
| JDB175 | JDB175 | Phase 1 Clinical | Shanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis | Details |
| SS-001 | SS-001 | Phase 1 Clinical | Zibo Baijichangsheng Pharmaceutical Co Ltd | Lymphoma, B-Cell | Details |
| BMS-986196 | 11C-BMS-986196 | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Sclerosis | Details |
| Docirbrutinib | AS-1763; BN-102; CB-1763 | Phase 1 Clinical | Bionova Pharmaceuticals (Shanghai) Ltd, Carna Biosciences Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Sofnobrutinib | AS-0871; AS-871 | Phase 1 Clinical | Carna Biosciences Inc | Autoimmune Diseases | Details |
| NX-2127 | NX-2127 | Phase 1 Clinical | Nurix Therapeutics Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
| TT-01488 | TT-01488 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Lymphoma, B-Cell; Solid tumours; Leukemia, B-Cell | Details |
| SYHA-1811 | SYHA-1811 | Phase 1 Clinical | Shanghai Runshi Pharmaceutical Technology Co Ltd | Lymphoma, B-Cell | Details |
| HSK-29116 | HSK-29116 | Phase 1 Clinical | Sichuan Haisco Pharmaceutical Co Ltd | Lymphoma, B-Cell | Details |
| YZJ-3058 | Phase 1 Clinical | Shanghai Haiyan Pharmaceutical Technology Co Ltd | Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| ZXBT-1158 | ZXBT-1158 | Phase 1 Clinical | Guangzhou BeBetter Medicine Technology Co | Lymphoma, B-Cell; Multiple Sclerosis | Details |
| Luxeptinib | CG026806; CG-806; CG’806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Evobrutinib | M-2951; MSC-2364447; MSC-2364447-C; MSC2364447C | Phase 1 Clinical | Merck Serono | Multiple Sclerosis, Relapsing-Remitting; Renal Insufficiency; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Erythematosus, Systemic; Hepatic Insufficiency | Details |
| GB-5121 | GB-5121; GB5121 | Clinical | Gossamer Bio Inc | Neurolymphomatosis; Central Nervous System Lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
